Medical Marijuana, Inc. Subsidiary Kannaway® Announces November 2021 as the Best Month in Company History for Japan Division

Rhea-AI Summary

Medical Marijuana, Inc. (MJNA) announced that its subsidiary, Kannaway® Japan, achieved its highest revenue month in November 2021. The company credits significant growth in Japan, anticipating the global CBD oil market to reach $5.3 billion by 2025, with Asia-Pacific as a key growth area. Executive statements highlight strong consumer interest and education efforts around CBD products. Kannaway® aims to lead the CBD market in Japan and globally.

Positive

• Kannaway® Japan recorded its best revenue month in company history in November 2021.
• The global CBD oil market is projected to reach $5.3 billion by 2025, indicating strong growth potential.
• Kannaway® is positioned as a market leader in the CBD category in Japan.

Negative

• None.

SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary Kannaway® Japan had its best revenue month in the Company’s history in November 2021.

“We’ve experienced tremendous growth and success in Japan this quarter,” said Kannaway® CEO Blake Schroeder. “We are excited about our continued development throughout Asia-Pacific as we continue to expand our presence throughout the region.”

According to Research and Markets, the global cannabidiol (CBD) oil market is expected to reach $5.3 billion by 2025 with Asia-Pacific as one of the fastest-growing regions.

“The popularity of CBD products in Japan is growing rapidly and we have been able to help further this trend by connecting with consumers to help them become educated on what CBD is and what high-quality CBD products are best for them,” said Kannaway® Global Sales Officer Peter Dale. “We are proud to be the market leaders in the CBD category in Japan and around the world.”

To learn more about Kannaway®, please visit the Company online at https://www.kannaway.com/.

About Kannaway®
Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.

About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations Contact:
Kathryn Brown
Account Director
CMW Media
P. 858-264-6600
kathryn@cmwmedia.com
www.cmwmedia.com

Investor Relations Contact:
P. (858) 283-4016
Investors@medicalmarijuanainc.com 

FAQ

What recent milestone did Medical Marijuana, Inc. achieve?

Medical Marijuana, Inc. announced that its subsidiary, Kannaway® Japan, had its best revenue month in November 2021.

What is the projected growth of the CBD oil market?

The global CBD oil market is expected to reach $5.3 billion by 2025.

How is Kannaway® performing in Japan?

Kannaway® claims to be the market leader in the CBD category in Japan and has experienced significant growth.

What are the expansion plans for Medical Marijuana, Inc. in Asia-Pacific?

Medical Marijuana, Inc. is focused on expanding its presence throughout the Asia-Pacific region.